相关实验视频
Updated: Jul 1, 2025

13:00
Engineering Antiviral Agents via Surface Plasmon Resonance
Published on: June 14, 2022
2.3K
控制COV-2变种细胞受体亲和度排名的分子相互作用的多样性及其实验变异性
Fredy Sussman1, Daniel S Villaverde1
1Department of Organic Chemistry, Faculty of Chemistry, Universidad de Santiago de Compostela, 15784 Santiago de Compostela, Spain.
International journal of molecular sciences
|March 13, 2024
概括
计算分析揭示了Delta和Omicron变异对宿主细胞的独特结合机制. 德尔塔表现出更高的结合亲和力,而Omicron则表现出更高的结合亲和力.
科学领域:
- 病毒学 病毒学
- 结构生物学 结构生物学
- 计算生物学 计算生物学
背景情况:
- 病毒感染性和毒性是由与宿主受体的尖端蛋白相互作用决定的.
- 了解关注变异 (VOC) 中的突变对于预测毒性和指导治疗策略至关重要.
研究的目的:
- 以计算方式评估来自野生类型,三角形和Omicron变体的尖端蛋白与ACE2受体的结合亲和力.
- 阐明不同VOC的尖峰受体相互作用背后的分子机制.
主要方法:
- 应用一套越来越复杂的计算协议.
- 计算三种VOC对ACE2细胞受体的尖端结合亲和力.
主要成果:
- 德尔塔和欧米克朗变种表现出不同的分子机制,用于尖端附着在ACE2受体上.
- 所有计算协议都预测,与野生型和Omicron相比,Delta变种的受体结合亲和力更高.
- 奥米克朗变体在尖端结合亲和力中显示出显著的变化,这与其尖端受体复合体的结构可塑性有关.
结论:
- 欧米克朗尖峰受体复合物的结构可塑性可能解释了体外结合结果的变化.
- 这种可塑性可能有助于Omicron变种相对较早的菌株的毒力相对较低.
- 还提出了进一步的假设,以解释Omicron的毒性减少.
更多相关视频
相关概念视频
The Two-State Receptor Model
1.9K
The two-state receptor model explains a drug's interaction with receptors, such as G protein-coupled receptors and ligand-gated ion channels, to induce or inhibit a biological response. When no natural ligands are present, a receptor exists in an equilibrium of inactive (Ri) and active (Ra) conformations. The inactive form does not produce a response, while the active form generates a basal effect known as constitutive activity.
The binding affinity of a drug determines its interaction with...
The binding affinity of a drug determines its interaction with...
1.9K
Drug-Receptor Bonds
2.8K
Drug-receptor bonds are formed through various chemical forces when drugs interact with target cells. Covalent bonds, strong and irreversible, are exemplified by DNA-alkylating anticancer agents that inhibit cell division. However, such irreversible drug binding lacks selectivity and can modify the DNA of the surrounding healthy cells. Covalent binding often contributes to tissue toxicity, as seen with chloroform and paracetamol metabolites binding to the liver, causing hepatotoxicity.
In...
In...
2.8K
Protein-Drug Binding: Mechanism and Kinetics
462
Protein-drug binding refers to the interaction between drugs and proteins within the body. This binding process can occur intracellularly, involving drug interactions with enzymes or receptors within cells, or extracellularly, involving plasma proteins in the blood.
Various forces drive these interactions, including hydrogen bonds, hydrophobic interactions, ionic bonds, electrostatic interactions, and van der Waals forces. These bonds enable drugs to bind to specific sites on proteins,...
Various forces drive these interactions, including hydrogen bonds, hydrophobic interactions, ionic bonds, electrostatic interactions, and van der Waals forces. These bonds enable drugs to bind to specific sites on proteins,...
462
Diversity of Antigen Receptors
582
Antigen receptors are essential components of the immune system crucial in defending the body against foreign invaders. These receptors are present on the surface of B and T cells, enabling them to recognize antigens and mount an appropriate immune response.
Before encountering any antigen, lymphocytes express these receptors. On B cells, the antigen receptor is a membrane-bound antibody molecule called BCR; on T cells, it is a T cell receptor or TCR. B and T cell receptors are composed of two...
Before encountering any antigen, lymphocytes express these receptors. On B cells, the antigen receptor is a membrane-bound antibody molecule called BCR; on T cells, it is a T cell receptor or TCR. B and T cell receptors are composed of two...
582
Leaky Scanning
5.1K
During most eukaryotic translation processes, the small 40S ribosome subunit scans an mRNA from its 5' end until it encounters the first start AUG codon. The large 60S ribosomal subunit then joins the smaller one to initiate protein synthesis. The location of the translation initiation is largely determined by the nucleotides near the start codon as there may be multiple translation initiation sites present on the mRNA. Marilyn Kozak discovered that the sequence RCCAUGG (where R...
5.1K
The Equilibrium Binding Constant and Binding Strength
12.9K
The equilibrium binding constant (Kb) quantifies the strength of a protein-ligand interaction. Kb can be calculated as follows when the reaction is at equilibrium:
12.9K

